Shares of Recursion Pharmaceuticals climbed after the company said it has agreed to purchase Rallybio's interest in a drug-development plan that aims to treat a rare genetic bone disease. The stock ...

This SonarSource project is a code analyzer for Java projects to help developers produce Clean Code. Information about the analysis of Java features is available here. To provide feedback (request a ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a ...

Morgan Stanley (NYSE: MS) reduced its price target on Recursion Pharmaceuticals (NASDAQ: RXRX) stock to $5.00 from $8.00 on Monday, while maintaining an Equalweight rating on the shares. According to ...

Recursion CEO: Biotech’s rainy season is not over — but we must race ahead The hard decisions we have to make when patient lives are on the line Adobe By Chris Gibson June 13, 2025 ...

Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. See why RXRX stock is a Hold.

Recursion Pharmaceuticals, Inc.’s Stock Price as of Market Close As of June 11, 2025, 2:02 PM, CST, Recursion Pharmaceuticals, Inc.’s stock price was $5.565. Recursion Pharmaceuticals, Inc. is up 2.11 ...

In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (RXRX 0.70%) is slimming down and streamlining. After the biotech updated its strategy to do so ...